Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company’s share

Gabather AB has appointed Pareto Securities as the Company’s liquidity provider.

The assignment will commence on January 14, 2025, and Pareto Securities will continuously place trading items on both bid and ask side in the order book for the PHI share and ensure that a predetermined spread is maintained in the share.

The purpose of the liquidity providing is to promote good liquidity and ensure a low spread between the bid and ask price in current trading.

For further information, please contact:

Michael Robin Witt, CEO

email: mrw@gabather.com

Tel. +46736872839

Gabather AB in brief

Gabather develops the next generation of therapeutics in the area if mental health. Gabather’s

proprietary GABA_A receptor modulators have a unique mechanism of action that can be the basis for the development of novel therapeutics for the treatment of major neuropsychiatric disorders.

Gabather is currently in a clinical development program for its most advanced clinical candidate, GT-002, in the treatment of schizophrenia and Gabather’s GABA_A receptor modulators have the potential to be effective in the treatment in disease areas that involve an imbalance in the GABA_A receptor system, such as Alzheimer’s disease, cognitive impairment  and autism.

Gabather is traded på First North Growth Market and Corpura Fondkommission AB acts as the company's Certified Advisor.